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Case report
Introduction
Coronary artery aneurysm (CAA) is a life-threat-
ening complication of Kawasaki disease (KD).
Thrombosis in KD with CAA may lead to morbid-
ity and mortality, such as myocardial infarction1).
Therefore, optimal treatment of children with KD
with CAA, is crucial for thromboprophylaxis.
Depending on the size of the aneurysm, second
antiplatelet agents or anticoagulants may be added
to aspirin therapy2).
We describe a 6-year-old girl who was treated
with warfarin after she had developed multiple,
long, and medium-sized CAAs in the left anterior
descending artery (LAD) and long segments of irreg-
ular dilatation and tortuosity in the right coro-
nary artery (RCA). The girl showed a refractory
response to conventional treatment of KD and
adjunctive steroid therapy, and was at a risk of
thrombosis due to turbulent flow inside the CAAs.
Case
The patient was a previously healthy, 6-year old
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girl. In August 2017, she was hospitalized at a hos-
pital for fever that lasted for 7 days, conjunctival
injection without any discharge, red lips and tongue,
enlarged cervical lymph node, truncal maculopapu-
lar polymorphous rash, and edematous changes on
both palms and soles. She was treated with intra-
venous immunoglobulin (2 g/kg) as the standard
treatment protocol for KD.
Despite the therapy, her symptoms waxed and
waned. Echocardiography showed diffuse coronary
artery ectasia of the left main coronary artery, an
aneurysm of the LAD, and an irregular fusiform
aneurysm and tortuous dilatation of the RCA (Fig.
1). Given these multiple CAAs, she was then referred
to our hospital, and hospitalized to the general ward.
The initial vital signs were as follows: blood pres-
sure, 121/71 mmHg; heart rate, 88 beats per minute;
temperature, 36.5。C; and alert mentality. Her weight
was 21 kg (25-50 percentile).
Initial laboratory findings showed a C-reactive
protein concentration of 27.0 mg/L and procalci-
tonin concentration of 0.67 ng/mL (reference value,
0.02-0.5 ng/mL). Other laboratory findings were
as follows: white blood cell count, 6.40 × 103/μL;
hemoglobin, 10.8 g/dL; hematocrit, 31.5%; platelet,
488 × 103/μL; serum sodium, 136 mmol/L; potassi-
um, 4.2 mmol/L; aspartate aminotransferase, 30
IU/L; alanine aminotransferase, 72 IU/L; albu-
min, 3.0 g/dL; total bilirubin, 0.5 mg/dL; and B-
type natriuretic peptide, 218.4 pg/mL. 
Adjunctive steroid therapy was performed in
addition to intravenous immunoglobulin and aspirin,
and no further manifestations of KD were noted.
However, echocardiography showed coronary arte-
riopathy with aneurysms (spindle-shaped LAD
ectasia of 5-6 mm [Z-score = 5.2] and RCA ecta-
sia of 4-6 mm [Z-score = 5.1]). Cardiac computed
tomography for evaluation of the distal coronary
arteries showed aneurysms in multiple coronary
segments, which were wider and longer than those
reported in the echocardiography performed at the
referring hospital (Fig. 2).
As per the 2017 American Heart Association
guidelines, KD with medium-sized CAAs does not
always require the administration of low-molec-
ular-weight heparin or warfarin as thrombopro-
phylaxis3). However, the anatomical features of the
CAAs in our patient could cause turbulent blood
flow inside the lesions, which is mentioned as a risk
factor for myocardial ischemia in the guidelines3).
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Fig. 1. Echocardiographic findings after the first intravenous immunoglobulin therapy. It shows the left main coronary artery and
proximal portion of the dilated left descending artery (arrow; diameter, 4.3-5.1 mm; Z-score = 5.0) (A) and a fusiform diffuse dilata-
tion of the right coronary artery (arrow; diameter, 5.6-6.0 mm; Z-score = 5.1) (B).
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Thus, we initiated long-term anticoagulation ther-
apy with warfarin (2.5 mg/day). International nor-
malized ratio (INR) remained within the target of
2-4 for 5 consecutive days without acute bleeding.
The concentrations of C-reactive protein and pro-
calcitonin normalized, and initial blood culture
showed no bacterial growth. On day 7, she was dis-
charged without residual manifestations of KD.
After 3 days, she visited the emergency depart-
ment (ED) for mild fever and erythematous skin
rash on her back, neck, and both legs. Laboratory
tests related to KD showed normal results. In addi-
tion, the rash recurred on the same site as before,
and disappeared spontaneously. She was discharged
without measuring INR because the rash was not
considered to be due to a potential coagulopathy.
Three days after the ED visit, she returned to the
outpatient department with evident petechiae.
Given a follow-up INR of 6.28, we concluded that
it was risky to continue warfarin therapy. After dis-
continuing the therapy, her INR normalized with-
in 2 days. Given her unusually high INR with the
dose of warfarin, we performed genetic assays for
warfarin-related genes to investigate the causes.
The assays showed that her CYP2C9 genotype was
*1/*3 (intermediate metabolizer) and her vitamin K
epoxide reductase complex 1 (VKORC1; -1639G>A)
genotype was AA. Because there are no dose-adjust-
ment guidelines for children with genetic warfarin
sensitivity, we decided to replace warfarin with
clopidogrel.
Follow-up echocardiography every 3 months
showed no further dilatation or thrombosis of the
CAAs. Moreover, a 29-month follow-up cardiac com-
puted tomography (January 2020) showed signif-
icant improvement of the RCA and LAD lesions,
even with residual mild dilatation and focal dilata-
tion of the left circumflex artery (Fig. 3).
Discussion
This case report shows clinical implications of the
genetic warfarin sensitivity in settings of antico-
agulation for KD with CAA, and the potential for
bleeding in cases of delayed detection of the sen-
sitivity. Two previous articles have shown that dose
adjustment and longer monitoring of INR are nec-
essary in warfarin therapy for children with KD
and associated warfarin sensitivity4,5).
CYP2C9 has 3 genetic variants, including wild-
type CYP2C9 *1, and variants *2 and *3. Variants
*2 and *3 reduce the enzymatic activity, and result
in relative sensitivity to warfarin compared to wild-
type CYP2C9 *1. The VKORC1 gene, another major
gene of warfarin sensitivity, encodes the vitamin K
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Fig. 2. Cardiac computed tomography findings after the second therapy. It shows a spindle-shaped coronary ectasia of the left main
coronary artery (arrow; length, about a bit more than 2.0 cm; diameter, 6.2 mm; Z-score = 6.1) (A) and a long fusiform aneurysm of
the right coronary artery (arrow; length, about 3.6 cm; diameter, 6.7 mm; Z-score = 5.6) (B). These findings are also seen in a 3-
dimensional reconstruction image (arrows; C).
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epoxide reductase enzyme that promotes vitamin K
recycling. A common non-coding variant, -1639G>A,
may increase warfarin sensitivity. In -1639A car-
riers who need warfarin therapy, initial and main-
tenance doses should be lower than in -1639G car-
riers6).
For children with variant alleles, such as CYP2C9
*1/*3, *2/*2, *2/*3, *3/*3, VKORC1 GA, or AA, it
takes longer to reach the maximum INR (about 2-
4 weeks after the first warfarin administration)6,7).
When reached, INR is higher in children with the
variants than in those with the wild-type gene6,7).
Therefore, in cases of children with genetic vari-
ants affecting warfarin metabolism, a hospital
length of stay of 3-5 days for warfarin mainte-
nance may be too short to prevent iatrogenic coag-
ulopathy, resulting in unexpected return visits to
EDs with bleeding. Given that the genotype-based,
therapeutic dose recommendations for warfarin
are available for adults, further studies are need-
ed to determine pediatric guidelines6).
Furthermore, because KD is characterized by poly-
morphic erythematous skin lesions, in children
with recently diagnosed KD, coagulopathy-induced
petechiae can be misdiagnosed as improving,
incompletely treated or refractory KD. Hence, it is
important to distinguish KD from coagulopathy. In
typical KD, polymorphic rash is followed by desqua-
mation8), and erythematous changes in the extrem-
ities and at the Bacille Calmette-Guérin inocula-
tion sites are common9). In coagulopathy, petechi-
ae do not blanch under pressure. If these differ-
ences are not recognized, there may be a delay in
detecting life-threatening bleeding. Thus, this
case suggests that history of recent anticoagula-
tion needs to be obtained in EDs.
In conclusion, this case suggests that iatrogenic
coagulopathy needs to be monitored in children with
KD associated with CAA who have undergone recent
anticoagulation. It is vital to obtain the relevant his-
tory, and if available, genetic assays for warfarin
sensitivity in the children. To prevent not only throm-
bosis but also bleeding, regular monitoring of INR
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Fig. 3. The 29-month follow-up cardiac computed tomography findings (January 2020). It shows the improved left main and ascend-
ing coronary arterial ectasia (arrow; length, 11 mm; diameter, 4.7 mm; Z-score = 4.0) with mild residual dilatation and focal dilata-
tion of the left circumflex artery (diameter, 4.2 mm) (A) and a right coronary arterial ectasia (arrow; diameter, 4.3 mm; Z-score =
2.9) with minimal residual coronary dilatation (B). These findings are also seen in a 3-dimensional reconstruction image (arrows; C).
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